GILD,L Stock Price and Quote

Peers: AMGN REGN VRTX BIIB ABBV BMY LLY MRK ALNY ARGX

| Held by: VTI VOO QQQ IVV SPY VTV XLV VIG QQQM IBB

Index	NDX, S&P 500
Market Cap	185.62B
Enterprise Value	206.90B
Income	-3.24B
Sales	30.54B
Book/sh	9.53
Cash/sh	3.94
Dividend Est.	3.25 (2.17%)
Dividend TTM	3.22 (2.15%)
Dividend Ex-Date	Sep 15, 2026
Dividend Gr. 3/5Y	2.67% 3.04%
Payout	46.60%
Employees	17000
IPO	Jan 22, 1992

P/E	-
Forward P/E	15.13
PEG	1.61
P/S	6.08
P/B	15.71
P/C	38.02
P/FCF	14.34
EV/EBITDA	14.11
EV/Sales	6.77
Quick Ratio	1.09
Current Ratio	1.27
Debt/Eq	2.22
LT Debt/Eq	2.01
Option/Short	Yes / Yes

EPS (ttm)	-2.66
EPS next Y	9.90
EPS next Q	2.13
EPS this Y	-105.73%
EPS next Y	2217.45%
EPS next 5Y	9.39%
EPS past 3/5Y	23.06% 133.64%
Sales past 3/5Y	2.83% 3.63%
EPS Y/Y TTM	-151.43%
Sales Y/Y TTM	6.05%
EPS Q/Q	-640.66%
Sales Q/Q	10.73%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	6.85% 5.47%

Insider Own	0.17%
Insider Trans	-8.03%
Inst Own	92.64%
Inst Trans	1.13%
ROA	-6.17%
ROE	-20.57%
ROIC	-9.09%
Gross Margin	79.66%
Oper. Margin	39.05%
Profit Margin	-10.61%
SMA20	6.73%
SMA50	11.57%
SMA200	11.93%
Trades

Shs Outstand	1.24B
Shs Float	1.24B
Short Float	1.87%
Short Ratio	3.04
Short Interest	23.18M
52W High	157.29 -4.83%
52W Low	108.46 38.02%
Volatility	2.17% 2.75%
ATR (14)	3.56
RSI (14)	70.14
Beta	0.36
Rel Volume	0.02
Avg Volume	7.63M
Volume	7,046

Perf Week	2.45%
Perf Month	14.03%
Perf Quarter	11.36%
Perf Half Y	0.50%
Perf YTD	21.97%
Perf Year	33.00%
Perf 3Y	94.31%
Perf 5Y	110.02%
Perf 10Y	87.66%
Recom	1.63
Target Price	158.96
Prev Close	148.86
Price	149.70
Change %	0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-26	Downgrade	Leerink Partners	Outperform → Market Perform	$127
Jul-06-26	Upgrade	HSBC Securities	Hold → Buy	$155
May-20-26	Upgrade	Maxim Group	Hold → Buy	$165
Mar-10-26	Initiated	Jefferies	Buy	$180
Feb-20-26	Initiated	Barclays	Equal Weight	$155
Feb-11-26	Reiterated	Needham	Buy	$140 → $170
Jan-07-26	Resumed	UBS	Buy	$145
Nov-24-25	Resumed	Truist	Buy	$140
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$140
Aug-19-25	Upgrade	Daiwa Securities	Neutral → Outperform	$128
Aug-08-25	Upgrade	Truist	Hold → Buy	$127
Jul-25-25	Upgrade	Needham	Hold → Buy	$133
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$125
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125

Show Previous Ratings

Aug-27-26 05:47PM	U.S. FDA Approves Gilead's Bixlenvo, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens (Business Wire)
Aug-26-26 04:05PM	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences (Business Wire)
02:20PM	ITOC Stockholders Have Rights - If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire)
09:29AM	Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug (Proactive)
Aug-25-26 03:30PM	Eli Lilly Is Pulling Away From the Rest of Healthcare (GuruFocus.com)
04:04PM	Loading…
Aug-24-26 04:04PM	GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict (Stocktwits)
02:36PM	Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition (Trefis)
06:31AM	European Commission Expands Role of Gilead's Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status (Business Wire)
Aug-19-26 10:44AM	Biotech Stocks Are Booming. What This Top Fund Is Buying Now. (Barrons.com)
06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
Aug-14-26 06:15PM	Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC (PR Newswire)
01:34PM	Gilead wins appeals court ruling against overseas drug imports (Quartz)
Aug-13-26 11:01AM	Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here. (MarketWatch)
Aug-10-26 01:01AM	GILD- An Attractive Biotech Stock with Solid Base Revenue Growth (MoneyShow)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
07:04AM	Loading…
Aug-06-26 07:04AM	MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data (Clinical Trials Arena)
Aug-05-26 03:01PM	Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ... (GuruFocus.com)
07:00AM	Earnings roundup: Gileads uncertain future, Pfizers crossroads and Mercks PCSK9 launch (BioPharma Dive)
01:06AM	Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ... (GuruFocus.com)
Aug-04-26 09:41PM	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results (Business Wire)
04:31PM	Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue (The Wall Street Journal)
04:12PM	Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up (Investor's Business Daily)
04:12PM	Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story (Barrons.com)
04:08PM	Gilead: Q2 Earnings Snapshot (Associated Press)
04:01PM	Gilead Sciences Announces Second Quarter 2026 Financial Results (Business Wire)
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-29-26 05:49AM	BMS and Gilead rule in the CAR-T space. Off-the-shelf developers arent trying to change that. (Pharma Voice)
Jul-28-26 05:48AM	Kalshi is expanding online betting in drug R&D unless detractors can stop it (Pharma Voice)
Jul-24-26 06:26AM	CHMP Recommends Gilead's Trodelvy Plus Keytruda in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer (Business Wire)
Jul-22-26 05:33AM	Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study (BioPharma Dive)
04:05PM	Loading…
Jul-21-26 04:05PM	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 (Business Wire)
10:00AM	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure (Business Wire)
Jul-17-26 12:55PM	Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. (Investor's Business Daily)
Jul-16-26 01:00PM	Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions (CryptoProwl)
08:00AM	Kalshi Will Offer Sports-Style Betting on Drug Trial Results (Bloomberg)
Jul-13-26 01:37PM	Own Regeneron For Biotech Growth? Incyte Is Making Its Case. (Trefis)
Jul-10-26 04:30PM	Gilead Sciences Inc. stock underperforms Friday when compared to competitors (MarketWatch)
Jul-07-26 04:30PM	Gilead Sciences Inc. stock outperforms competitors on strong trading day (MarketWatch) +5.21%
Jul-06-26 12:00PM	The Cancer Therapy Strategy VERAXA Is Betting the Company On (Exec Edge)
09:47AM	Okta upgraded, Datadog downgraded: Wall Street's top analyst calls (The Fly)
Jun-30-26 04:10PM	Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial (Exec Edge)
Jun-24-26 04:29PM	U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer (Business Wire)
02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
Jun-23-26 08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
07:45AM	European Commission Approves Trodelvy as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors (Business Wire)
Jun-22-26 11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge)
Jun-18-26 10:34AM	VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 (Exec Edge)
Jun-11-26 08:30AM	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership (Business Wire)
Jun-09-26 08:21AM	Merck, Gilead report mixed outcomes in key lung cancer, HIV studies (BioPharma Dive)
Jun-08-26 04:35PM	Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment (Business Wire)
04:30PM	Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study (Business Wire)
Jun-04-26 08:08PM	Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 (Stocktwits)
04:15PM	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline (Business Wire)
Jun-03-26 07:09AM	Gilead eyes PBC expansion for Livdelzi on positive one-year data (Clinical Trials Arena)
Jun-02-26 08:30AM	Gilead's Livdelzi (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) (Business Wire)
May-29-26 06:17AM	Allogene CEO to step down; Agios drug fails key test (BioPharma Dive)
May-28-26 06:47AM	FDA accelerated approval of Hepcludex significant milestone for US HDV market (Clinical Trials Arena)
May-27-26 02:00AM	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1-1.67xULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar) (Business Wire)
May-26-26 06:16AM	Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine (BioPharma Dive)
May-22-26 03:08PM	GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment (Stocktwits)
02:00PM	FDA Grants Accelerated Approval to Gilead's Hepcludex (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) (Business Wire)
07:47AM	Gilead Receives CHMP Positive Opinion for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors (Business Wire)
07:19AM	Gilead Sciences completes Tubulis acquisition for $5bn (Pharmaceutical Technology)
07:13AM	Gilead Sciences acquires Tubulis for $5bn (Pharmaceutical Business Review)
May-21-26 05:00PM	New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology (Business Wire)
09:30AM	Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio (Business Wire)
03:30AM	Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease (Business Wire)
May-20-26 09:43AM	Cigna downgraded, Humana upgraded: Wall Street's top analyst calls (The Fly)
May-18-26 08:35AM	Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) (InvestorsHub)
May-14-26 09:21PM	Gilead Prices $3 Billion of Senior Unsecured Notes (Business Wire)
May-13-26 08:30AM	Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 (Business Wire)
May-11-26 01:17PM	Here's how much Moderna's stock has rallied off renewed focus on hantavirus research (MarketWatch)
May-08-26 12:59PM	Gilead posts positive Q1 buoyed by HIV drug growth (Pharmaceutical Technology)
May-07-26 04:51PM	Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? (Barrons.com)
04:39PM	Gilead Sciences Expects Loss This Year on Acquired R&D Expenses (The Wall Street Journal)
04:09PM	Gilead: Q1 Earnings Snapshot (Associated Press)
04:09PM	Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy (Investor's Business Daily)
04:01PM	Gilead Sciences Announces First Quarter Financial Results (Business Wire)
04:52AM	Lilly, Gilead lead pharmas M&A boom (Pharma Voice)
May-06-26 06:48PM	Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com)
09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
06:12AM	California's highest court to consider whether drugmakers have 'duty to innovate' (Reuters)
May-01-26 06:00AM	Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences (Business Wire)
Apr-29-26 08:30AM	U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir (Business Wire)
Apr-28-26 11:21AM	Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. (Barrons.com)
08:45AM	Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel (Business Wire)
Apr-22-26 04:05PM	Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 (Business Wire)
07:57AM	FDA approves MSDs once-daily HIV combo Idvynso (Pharmaceutical Technology)
Apr-21-26 04:00AM	Lillys CAR-T Kelonia deal cements Big Pharmas in vivo push (Pharma Voice)
Apr-20-26 04:51PM	Why Eli Lilly is betting $7B on this cancer drug (Yahoo Finance Video)
Apr-17-26 08:30AM	Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer (Business Wire)
06:04AM	Lillys obesity pill off to a strong start; OpenAI debuts new drug discovery tool (BioPharma Dive)
Apr-14-26 12:00PM	PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access (Business Wire)
Apr-10-26 07:10AM	RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders (BioPharma Dive)
Apr-09-26 06:24PM	PLTR, RIVN Gain Favor As INTC Momentum Fades (GuruFocus.com)
08:30AM	Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE (Business Wire)
Apr-08-26 12:44PM	Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline (GuruFocus.com)
08:12AM	With 3 quick buyouts, Gilead leans into its latest transformation (BioPharma Dive)
Apr-07-26 03:21PM	Gilead Sciences Is Betting on a Bavarian Biotech For Its Comeback (Moby)
12:43PM	Health Care Roundup: Market Talk (The Wall Street Journal)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Chairman & CEOMr. Daniel Patrick O'Day

Executive VP & CFOMr. Andrew D. Dickinson

Chief Commercial & Corporate Affairs OfficerMs. Johanna Mercier

Ph.D.Dr. Dietmar P. Berger M.D.

Senior VPMs. Erin E. Burkhart

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WELTERS ANTHONY	Director	Aug 26 '26	Option Exercise	61.06	18,000	1,099,052	23,176	Aug 27 06:44 PM
WELTERS ANTHONY	Director	Aug 26 '26	Sale	148.62	18,000	2,675,220	12,894	Aug 27 06:44 PM
ANTHONY WELTERS	Director	Aug 26 '26	Proposed Sale	148.77	18,000	2,677,860		Aug 26 04:16 PM
Bluestone Jeffrey	Director	Aug 20 '26	Option Exercise	67.04	5,000	335,207	11,882	Aug 21 07:22 PM
Bluestone Jeffrey	Director	Aug 20 '26	Sale	145.02	5,000	725,078	10,066	Aug 21 07:22 PM
JEFFREY BLUESTONE	Director	Aug 20 '26	Proposed Sale	147.60	5,000	738,000		Aug 20 04:36 PM
Dickinson Andrew D	Chief Financial Officer	Aug 17 '26	Sale	138.36	3,000	415,080	165,646	Aug 18 07:06 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Aug 17 '26	Option Exercise	67.07	25,000	1,676,773	146,234	Aug 18 06:54 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Aug 17 '26	Sale	137.64	28,000	3,853,908	118,234	Aug 18 06:54 PM
JOHANNA MERCIER	Officer	Aug 17 '26	Proposed Sale	137.64	28,000	3,853,908		Aug 17 04:18 PM
ANDREW DICKINSON	Officer	Aug 17 '26	Proposed Sale	138.36	3,000	415,080		Aug 17 04:11 PM
O'Day Daniel Patrick	Chairman & CEO	Aug 03 '26	Sale	130.31	15,000	1,954,694	592,133	Aug 04 05:40 PM
DANIEL O'DAY	Director	Aug 03 '26	Proposed Sale	130.21	55,000	7,161,550		Aug 03 04:41 PM
Dickinson Andrew D	Chief Financial Officer	Jul 15 '26	Sale	129.93	3,000	389,777	168,646	Jul 16 06:08 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Jul 15 '26	Sale	129.92	3,000	389,758	121,234	Jul 16 04:54 PM
JOHANNA MERCIER	Officer	Jul 15 '26	Proposed Sale	129.92	3,000	389,758		Jul 15 04:13 PM
ANDREW DICKINSON	Officer	Jul 15 '26	Proposed Sale	129.93	3,000	389,777		Jul 15 04:10 PM
O'Day Daniel Patrick	Chairman & CEO	Jul 01 '26	Sale	126.29	15,000	1,894,400	607,133	Jul 02 04:14 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Jun 15 '26	Sale	123.92	3,000	371,762	124,234	Jun 16 06:02 PM
Dickinson Andrew D	Chief Financial Officer	Jun 15 '26	Sale	125.40	3,000	376,200	171,646	Jun 16 05:53 PM
ANDREW DICKINSON	Officer	Jun 15 '26	Proposed Sale	125.40	3,000	376,200		Jun 15 04:30 PM
JOHANNA MERCIER	Officer	Jun 15 '26	Proposed Sale	123.92	3,000	371,762		Jun 15 04:09 PM
O'Day Daniel Patrick	Chairman & CEO	Jun 01 '26	Sale	131.46	15,000	1,971,847	617,567	Jun 02 06:04 PM
DANIEL O'DAY	Director	Jun 01 '26	Proposed Sale	134.43	35,000	4,705,050		Jun 01 04:45 PM
Dickinson Andrew D	Chief Financial Officer	May 15 '26	Sale	132.27	3,000	396,810	173,191	May 18 05:50 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	May 15 '26	Option Exercise	66.64	25,000	1,666,000	153,779	May 18 05:45 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	May 15 '26	Sale	131.29	28,000	3,676,199	125,779	May 18 05:45 PM
JOHANNA MERCIER	Officer	May 15 '26	Proposed Sale	131.29	28,000	3,676,198		May 15 04:09 PM
ANDREW DICKINSON	Officer	May 15 '26	Proposed Sale	132.27	3,000	396,810		May 15 04:07 PM
O'Day Daniel Patrick	Chairman & CEO	Apr 28 '26	Sale	129.16	10,000	1,291,608	632,567	Apr 29 05:53 PM
DANIEL O'DAY	Officer	Apr 28 '26	Proposed Sale	129.16	10,000	1,291,609		Apr 28 04:12 PM
Dickinson Andrew D	Chief Financial Officer	Apr 15 '26	Sale	140.96	3,000	422,880	176,191	Apr 16 06:41 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Apr 15 '26	Sale	140.96	3,000	422,880	128,779	Apr 16 06:40 PM
JOHANNA MERCIER	Officer	Apr 15 '26	Proposed Sale	140.96	3,000	422,880		Apr 15 04:12 PM
ANDREW DICKINSON	Officer	Apr 15 '26	Proposed Sale	140.96	3,000	422,880		Apr 15 04:08 PM
O'Day Daniel Patrick	Chairman & CEO	Mar 27 '26	Sale	136.82	10,000	1,368,162	642,567	Mar 30 05:59 PM
DANIEL O'DAY	Officer	Mar 27 '26	Proposed Sale	136.82	10,000	1,368,162		Mar 27 04:03 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Mar 16 '26	Sale	144.23	3,000	432,690	131,779	Mar 17 06:56 PM
Dickinson Andrew D	Chief Financial Officer	Mar 16 '26	Sale	144.23	3,000	432,690	179,191	Mar 17 06:14 PM
JOHANNA MERCIER	Officer	Mar 16 '26	Proposed Sale	144.23	3,000	432,690		Mar 16 04:06 PM
ANDREW DICKINSON	Officer	Mar 16 '26	Proposed Sale	144.23	3,000	432,690		Mar 16 04:06 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 27 '26	Sale	144.79	10,000	1,447,859	642,308	Mar 02 04:46 PM
DANIEL O'DAY	Officer	Feb 27 '26	Proposed Sale	144.79	10,000	1,447,859		Feb 27 04:10 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Feb 17 '26	Option Exercise	66.64	25,000	1,666,000	148,288	Feb 18 05:22 PM
Mercier Johanna	Chief Comm & Corp Aff Officer	Feb 17 '26	Sale	154.44	28,000	4,324,228	120,288	Feb 18 05:22 PM
Dickinson Andrew D	Chief Financial Officer	Feb 17 '26	Sale	154.43	3,000	463,290	167,779	Feb 18 05:11 PM
JOHANNA MERCIER	Officer	Feb 17 '26	Proposed Sale	154.44	28,000	4,324,228		Feb 17 04:07 PM
ANDREW DICKINSON	Officer	Feb 17 '26	Proposed Sale	154.43	3,000	463,290		Feb 17 04:05 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 05 '26	Option Exercise	66.01	115,640	7,633,396	729,552	Feb 06 04:22 PM
O'Day Daniel Patrick	Chairman & CEO	Feb 05 '26	Sale	150.00	115,640	17,346,000	613,912	Feb 06 04:22 PM
DANIEL O'DAY	Officer	Feb 05 '26	Proposed Sale	150.00	115,640	17,346,000		Feb 05 04:05 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 28 '26	Sale	139.89	10,000	1,398,911	556,698	Jan 29 05:23 PM
DANIEL O'DAY	Officer	Jan 28 '26	Proposed Sale	139.89	10,000	1,398,911		Jan 28 05:02 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 23 '26	Option Exercise	66.01	115,640	7,633,396	682,338	Jan 26 07:29 PM
O'Day Daniel Patrick	Chairman & CEO	Jan 23 '26	Sale	135.00	115,640	15,611,400	566,698	Jan 26 07:29 PM
DANIEL O'DAY	Officer	Jan 23 '26	Proposed Sale	135.00	115,640	15,611,400		Jan 23 04:03 PM
DEBORAH TELMAN	Officer	Jan 22 '26	Proposed Sale	129.11	29,215	3,771,949		Jan 22 04:32 PM
Bluestone Jeffrey	Director	Jan 20 '26	Option Exercise	67.45	5,000	337,250	13,920	Jan 21 04:26 PM
Bluestone Jeffrey	Director	Jan 20 '26	Sale	123.50	5,000	617,500	8,920	Jan 21 04:26 PM
JEFFREY BLUESTONE	Director	Jan 20 '26	Proposed Sale	123.50	5,000	617,500		Jan 20 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '26	Sale	124.31	3,000	372,930	150,503	Jan 16 06:18 PM
Mercier Johanna	Chief Commercial Officer	Jan 15 '26	Sale	124.31	3,000	372,930	103,221	Jan 16 06:10 PM
JOHANNA MERCIER	Officer	Jan 15 '26	Proposed Sale	124.31	3,000	372,930		Jan 15 04:02 PM
ANDREW DICKINSON	Officer	Jan 15 '26	Proposed Sale	124.31	3,000	372,930		Jan 15 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	Dec 29 '25	Sale	124.83	10,000	1,248,272	566,698	Dec 30 04:23 PM
DANIEL O'DAY	Officer	Dec 29 '25	Proposed Sale	124.83	10,000	1,248,272		Dec 29 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Dec 15 '25	Sale	122.00	3,000	366,000	153,503	Dec 16 06:31 PM
Mercier Johanna	Chief Commercial Officer	Dec 15 '25	Sale	122.00	3,000	366,000	106,221	Dec 16 06:12 PM
JOHANNA MERCIER	Officer	Dec 15 '25	Proposed Sale	122.00	3,000	366,000		Dec 15 04:04 PM
ANDREW DICKINSON	Officer	Dec 15 '25	Proposed Sale	122.00	3,000	366,000		Dec 15 04:04 PM
Bluestone Jeffrey	Director	Nov 28 '25	Option Exercise	64.92	5,000	324,600	13,920	Dec 01 06:11 PM
Bluestone Jeffrey	Director	Nov 28 '25	Sale	125.08	5,000	625,400	8,920	Dec 01 06:11 PM
Kramer Kelly A.	Director	Nov 26 '25	Option Exercise	81.00	2,806	227,286	4,145	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 28 '25	Option Exercise	81.00	2,805	227,205	4,144	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 26 '25	Sale	127.11	2,806	356,671	1,339	Dec 01 04:54 PM
Kramer Kelly A.	Director	Nov 28 '25	Sale	127.10	2,805	356,516	1,339	Dec 01 04:54 PM
O'Day Daniel Patrick	Chairman & CEO	Nov 28 '25	Sale	126.54	10,000	1,265,444	571,203	Dec 01 04:50 PM
DANIEL O'DAY	Officer	Nov 28 '25	Proposed Sale	126.54	10,000	1,265,444		Nov 28 01:05 PM
JEFFREY BLUESTONE	Director	Nov 28 '25	Proposed Sale	125.08	5,000	625,400		Nov 28 01:02 PM
KELLY KRAMER	Director	Nov 26 '25	Proposed Sale	127.12	5,611	713,270		Nov 26 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Nov 17 '25	Sale	125.23	2,500	313,075	154,555	Nov 18 07:00 PM
Mercier Johanna	Chief Commercial Officer	Nov 17 '25	Option Exercise	66.64	25,000	1,666,000	135,193	Nov 18 06:51 PM
Mercier Johanna	Chief Commercial Officer	Nov 17 '25	Sale	125.86	28,000	3,524,173	107,193	Nov 18 06:51 PM
JOHANNA MERCIER	Officer	Nov 17 '25	Proposed Sale	125.86	28,000	3,524,173		Nov 17 04:06 PM
ANDREW DICKINSON	Officer	Nov 17 '25	Proposed Sale	125.23	2,500	313,075		Nov 17 04:05 PM
Telman Deborah H	EVP, Corporate Affairs & GC	Nov 12 '25	Option Exercise	65.35	53,646	3,505,885	79,641	Nov 13 07:36 PM
Telman Deborah H	EVP, Corporate Affairs & GC	Nov 12 '25	Sale	122.85	53,646	6,590,487	43,676	Nov 13 07:36 PM
DIANE E WILFONG	Officer	Nov 13 '25	Proposed Sale	127.02	3,500	444,556		Nov 13 05:07 PM
DEBORAH TELMAN	Officer	Nov 12 '25	Proposed Sale	122.56	55,646	6,819,974		Nov 12 04:36 PM
O'Day Daniel Patrick	Chairman & CEO	Oct 28 '25	Sale	119.39	10,000	1,193,926	581,203	Oct 29 04:14 PM
DANIEL ODAY	Officer	Oct 28 '25	Proposed Sale	119.39	10,000	1,193,926		Oct 28 05:47 PM
Dickinson Andrew D	Chief Financial Officer	Oct 15 '25	Sale	118.08	2,500	295,200	157,055	Oct 16 09:35 PM
Mercier Johanna	Chief Commercial Officer	Oct 15 '25	Sale	118.08	3,000	354,240	110,193	Oct 16 09:28 PM
ANDREW DICKINSON	Officer	Oct 15 '25	Proposed Sale	118.08	2,500	295,200		Oct 15 04:05 PM
JOHANNA MERCIER	Officer	Oct 15 '25	Proposed Sale	118.08	3,000	354,240		Oct 15 04:03 PM
O'Day Daniel Patrick	Chairman & CEO	Sep 29 '25	Sale	111.66	10,000	1,116,564	591,203	Sep 30 04:57 PM
DANIEL O'DAY	Officer	Sep 29 '25	Proposed Sale	111.66	10,000	1,116,564		Sep 29 04:09 PM
Mercier Johanna	Chief Commercial Officer	Sep 15 '25	Sale	113.57	3,000	340,710	113,193	Sep 16 05:16 PM
Dickinson Andrew D	Chief Financial Officer	Sep 15 '25	Sale	113.57	2,500	283,925	159,555	Sep 16 05:12 PM
ANDREW DICKINSON	Officer	Sep 15 '25	Proposed Sale	113.57	2,500	283,925		Sep 15 04:38 PM

Peers: MKL TRV CB WRB AFG AIG CINF AXS EG BRK-A

| Held by: VTI VOO VO IVV SPY RSP VTV XLF VOE SPLV

Index	S&P 500
Market Cap	22.60B
Enterprise Value	-
Income	1.69B
Sales	18.69B
Book/sh	93.52
Cash/sh	-
Dividend Est.	-
Dividend TTM	0.25 (0.22%)
Dividend Ex-Date	Aug 19, 2026
Dividend Gr. 3/5Y	0.00% 0.00%
Payout	3.14%
Employees	13100
IPO	Mar 13, 1959

P/E	13.54
Forward P/E	-
PEG	-
P/S	1.21
P/B	1.18
P/C	-
P/FCF	8.21
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	0.70
Debt/Eq	0.47
LT Debt/Eq	0.47
Option/Short	Yes / Yes

EPS (ttm)	8.16
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	33.13% -
Sales past 3/5Y	9.53% 5.99%
EPS Y/Y TTM	29.79%
Sales Y/Y TTM	3.50%
EPS Q/Q	15.65%
Sales Q/Q	3.93%
Earnings	Aug 03 BMO
EPS/Sales Surpr.	- -

Insider Own	19.95%
Insider Trans	-0.22%
Inst Own	62.39%
Inst Trans	-0.10%
ROA	1.96%
ROE	9.21%
ROIC	6.02%
Gross Margin	-
Oper. Margin	14.04%
Profit Margin	9.02%
SMA20	-1.95%
SMA50	-2.87%
SMA200	1.72%
Trades

Shs Outstand	204.40M
Shs Float	163.64M
Short Float	2.52%
Short Ratio	5.03
Short Interest	4.13M
52W High	121.01 -8.62%
52W Low	95.10 16.27%
Volatility	1.28% 1.67%
ATR (14)	1.83
RSI (14)	39.50
Beta	0.50
Rel Volume	0.00
Avg Volume	821.16K
Volume	1

Perf Week	0.68%
Perf Month	-4.98%
Perf Quarter	6.78%
Perf Half Y	0.50%
Perf YTD	5.00%
Perf Year	14.56%
Perf 3Y	77.69%
Perf 5Y	95.60%
Perf 10Y	166.89%
Recom	3.00
Target Price	82.00
Prev Close	109.82
Price	110.57
Change %	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-02-16	Reiterated	Deutsche Bank	Hold	$42 → $43
Aug-06-15	Reiterated	Deutsche Bank	Hold	$48 → $44
Mar-24-14	Downgrade	Deutsche Bank	Buy → Hold	$53 → $51
Sep-04-13	Initiated	Deutsche Bank	Buy	$52
Jun-23-09	Initiated	Susquehanna Financial	Positive

Aug-04-26 11:32AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Aug-03-26 08:17AM	Loews Reports Higher Second-Quarter Profit as Revenue Continues to Grow (InvestorsHub)
07:43AM	Hotels and pipelines drive Loews profits higher as insurance underwriting softens (Proactive)
06:05AM	Loews: Q2 Earnings Snapshot (Associated Press)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $444 MILLION FOR THE SECOND QUARTER OF 2026 (PR Newswire)
04:21AM	Loading…
04:21AM	Palantir and other companies set to report earnings (MarketWatch)
Jul-14-26 10:00AM	Loews Corporation to Release Second Quarter 2026 Results on August 3, 2026 (PR Newswire)
May-12-26 11:45AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
May-04-26 10:14AM	Loews reports year-over-year drop in profit (Proactive) -5.86%
10:14AM	Loews Corporation reports year-over-year drop in profit (Proactive)
08:18AM	Dow drops further, dragging S&P 500 and Nasdaq into the red (Proactive)
06:05AM	Loews: Q1 Earnings Snapshot (Associated Press)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $337 MILLION FOR THE FIRST QUARTER OF 2026 (PR Newswire)
May-03-26 02:00PM	Jobs Report, Palantir, Pinterest, AMD, PayPal, Disney, and More to Watch This Week (Barrons.com)
Apr-14-26 10:00AM	Loews Corporation to Release First Quarter 2026 Results on May 4, 2026 (PR Newswire)
01:32PM	Loading…
Mar-12-26 01:32PM	3 High-Volume ETF Options to Trade Now and Profit from Hot Market Themes (Barchart)
Feb-13-26 08:01AM	Buy This Stock to Own a Piece of Ferrari. It's a Low-Risk Bet for Value Seekers. (Barrons.com)
Feb-10-26 11:08AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Feb-09-26 10:33AM	Loews Smashes 52-Week High After Strong Quarter (Benzinga)
09:41AM	Loews reports higher Q4 and full-year profit (Proactive)
09:41AM	Loews Corporation reports higher Q4 and full-year profit (Proactive)
06:15AM	Loews: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $402 MILLION FOR THE FOURTH QUARTER OF 2025 AND $1,667 MILLION FOR THE FULL YEAR (PR Newswire)
Feb-06-26 07:00PM	Super Bowl LX, Coinbase earnings, jobs data & CPI: What to Watch (Yahoo Finance Video)
Jan-22-26 09:45AM	Loews Hotels & Co Announces Americana by Loews Hotels in Arlington, Texas (PR Newswire)
Jan-20-26 10:00AM	Loews Corporation to Release Fourth Quarter 2025 Results on February 9, 2026 (PR Newswire)
Jan-05-26 08:25AM	Versant set to trade on Nasdaq: LightShed's Rich Greenfield on what to expect (CNBC TV)
Dec-12-25 04:12AM	Loews Stock: Is L Outperforming the Financial Services Sector? (Barchart)
Dec-11-25 07:46AM	Loews Corporation Comments on Delaware Supreme Court's Ruling (PR Newswire)
Dec-06-25 12:34AM	Jim Cramer on Loews Corporation: "Good Opportunity Here" (Insider Monkey)
04:00AM	Loading…
Nov-19-25 04:00AM	Stop Sleeping on These 3 Stocks (Seriously) (Motley Fool)
Nov-11-25 11:19AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Nov-03-25 06:36AM	Loews Corporation Elects Dino Robusto to Its Board of Directors (PR Newswire)
06:06AM	Loews: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $504 MILLION FOR THE THIRD QUARTER OF 2025 (PR Newswire)
Nov-02-25 07:40AM	Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week (Yahoo Finance)
Oct-31-25 07:00PM	SNAP benefits expire, open enrollment, earnings: What to Watch (Yahoo Finance Video)
Oct-14-25 10:00AM	Loews Corporation to Release Third Quarter 2025 Results on November 3, 2025 (PR Newswire)
Sep-22-25 10:08AM	Is Loews Corporation Stock Outperforming the Dow? (Barchart)
Aug-26-25 11:51AM	Do Wall Street Analysts Like Loews Stock? (Barchart)
Aug-05-25 04:05PM	Loews Corporation Elects Jennifer VanBelle to Its Board of Directors (PR Newswire)
11:32AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Aug-04-25 08:36AM	Loews Corp.'s Q2 Earnings Jump As Investment Income And Insurance Underwriting Shine (Benzinga)
06:05AM	Loews: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $391 MILLION FOR THE SECOND QUARTER OF 2025 (PR Newswire)
05:39AM	Stock Markets Today: Dow set for 200-point gain, S&P 500 and Nasdaq seen higher after Friday's tariff and jobs-fueled selloff. (MarketWatch)
05:39AM	U.S. stock futures poised for a rebound after jobs selloff on Friday (MarketWatch)
Jul-16-25 10:03AM	CNA Financial Hits Another 52-Week Low. Is This the Kiss of Death for Loews? (Barchart)
09:47AM	Mamdani Talks Intifada, Taxes in Grilling by Business Leaders (Bloomberg)
Jul-15-25 10:00AM	Loews Corporation to Release Second Quarter 2025 Results on August 4, 2025 (PR Newswire)
Jun-20-25 07:33AM	Is Loews Stock Outperforming the Nasdaq? (Barchart)
Jun-06-25 12:30AM	Here Come the Berkshire Hathaway Wannabes (Barrons.com)
May-13-25 02:23PM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
May-05-25 06:04AM	Loews: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $370 MILLION FOR THE FIRST QUARTER OF 2025 (PR Newswire)
Apr-21-25 01:15PM	ABEQ: Focused On High-Quality Companies With Margin Of Safety (Seeking Alpha)
Apr-15-25 10:00AM	Loews Corporation to Release First Quarter 2025 Results on May 5, 2025 (PR Newswire)
Feb-17-25 10:43AM	The Tisch family just appointed its third generation of CEO at $18.5 billion Loews Corporationhes pledging to focus on one job (Fortune)
Feb-11-25 12:16PM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Feb-10-25 09:08AM	Loews Q4: Earnings Take A Hit On Pension Charge, But Pipelines And Buybacks Offer Silver Lining (Benzinga)
06:57AM	Loews Just Dropped a $187M Bombshell--But Its $3.3B War Chest Has Investors Watching (GuruFocus.com)
06:15AM	Loews: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $187 MILLION FOR THE FOURTH QUARTER OF 2024 AND $1,414 MILLION FOR THE FULL YEAR (PR Newswire)
Jan-21-25 10:00AM	Loews Corporation to Release Fourth Quarter 2024 Results on February 10, 2025 (PR Newswire)
Jan-09-25 09:00PM	I Dont Think Theres Much Left: L.A. Fires Leave Thousands Looking for Temporary Housing (The Wall Street Journal)
Dec-15-24 08:00AM	How an Ivy League Police Commissioner Hunted an Ivy League Murder Suspect (The Wall Street Journal)
Nov-12-24 11:24AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Nov-05-24 12:05AM	Decoding Loews Corp (L): A Strategic SWOT Insight (GuruFocus.com)
Nov-04-24 07:58AM	Loews Reports Strong Q3 With 58% Net Income Surge, Backed by CNA Financial And Boardwalk Pipelines (Benzinga)
07:28AM	Loews' third-quarter profit jumps on investment income boost (Reuters)
06:06AM	Loews: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $401 MILLION FOR THE THIRD QUARTER OF 2024 (PR Newswire)
Oct-15-24 10:00AM	Loews Corporation to Release Third Quarter 2024 Results on November 4, 2024 (PR Newswire)
Sep-09-24 04:15PM	Loews Corporation Announces Favorable Resolution of Boardwalk Pipelines Acquisition Litigation (PR Newswire)
Aug-26-24 07:01PM	Insider Sale: Kenneth Siegel Divests Shares of Loews Corp (L) (GuruFocus.com)
Aug-06-24 11:12AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Aug-02-24 06:17AM	3 Holding Company Stocks to Buy Other Than Berkshire Hathaway (InvestorPlace)
Jul-30-24 01:06AM	Loews Corp (L) Uncovered: Key Opportunities and Threats Ahead (GuruFocus.com)
Jul-29-24 03:31PM	Wall Street is still jittery on GLP-1s (Yahoo Finance)
12:29PM	Top Stock Movers Now: Tesla, Onsemi, McDonald's, and More (Investopedia)
08:52AM	Loews Clocks Strong Q2 Performance, CEO James Tisch To Retire, Benjamin Tisch Named Successor (Benzinga)
07:54AM	Loews CEO James Tisch to step down after 25 years (Reuters)
06:08AM	Loews: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $369 MILLION FOR THE SECOND QUARTER OF 2024 (PR Newswire)
06:00AM	Loews Corporation Announces CEO Transition: (PR Newswire)
Jul-09-24 10:00AM	Loews Corporation to Release Second Quarter 2024 Results on July 29, 2024 (PR Newswire)
Jun-03-24 12:54PM	Loews Hotels' Tisch: Pent-up demand for lodging has waned while other areas are getting stronger (CNBC TV)
May-22-24 07:06PM	Insider Sale: SVP & Chief Investment Officer Richard Scott Sells 9,045 Shares of Loews Corp (L) (GuruFocus.com)
May-14-24 10:41AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
May-07-24 05:01PM	Loews Corp (L) (Q1 2024) Earnings Call Transcript Highlights: Strong Performance with Notable ... (GuruFocus.com)
09:53AM	CNA Financial Corporation (NYSE:CNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:03AM	Decoding Loews Corp (L): A Strategic SWOT Insight (GuruFocus.com)
May-06-24 10:53AM	L Stock Earnings: Loews Reported Results for Q1 2024 (InvestorPlace)
10:20AM	The Marcus Corporation (NYSE:MCS) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:02AM	Loews Corp (L) Reports Strong First Quarter 2024 Earnings, Net Income Rises 22% (GuruFocus.com)
07:02AM	Loews reports higher profit on strong returns on investment income (Reuters)
06:08AM	Loews: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $457 MILLION FOR THE FIRST QUARTER OF 2024 (PR Newswire)
May-03-24 06:00AM	Loblaw Releases 2023 ESG Report (PR Newswire)
Apr-16-24 10:00AM	Loews Corporation to Release First Quarter 2024 Results on May 6, 2024 (PR Newswire)

Loews Corp. is a holding company, which engages in the business of commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, and operation of a chain of hotels. It operates through the following segments: CNA Financial, Boardwalk Pipelines, Loews Hotels and Co, and Corporate. The CNA Financial segment is involved in the sale of property and casualty insurance products and services, including surety, primarily through a network of independent agents, brokers, and managing general underwriters. The Boardwalk Pipelines segment focuses on midstream portion of the natural gas and NGLs industry, providing transportation, and storage for those commodities. The Loews Hotels and Co segment refers to a chain of hotels, which are in the United States and one of which is in Canada. The Corporate segment consists of investment income from the parent company's cash and investments, parent company interest expense, and other unallocated parent company expenses. The company was founded by Laurence A. Tisch and Preston Robert Tisch on November 12, 1969 and is headquartered in New York, NY.

CEOMr. Benjamin J. Tisch

Senior VP & CFOMs. Jane J. Wang

Senior Vice PresidentMr. Kenneth I. Siegel

VP & DirectorMr. Alexander H. Tisch

Senior VP & Chief Investment OfficerMr. David Eugene Czerniecki C.F.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Robusto Dino	Director	May 29 '26	Buy	104.74	5,000	523,700	10,235	Jun 01 08:59 AM
Robusto Dino	Director	May 05 '26	Buy	105.44	5,000	527,200	5,235	May 05 04:16 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Mar 11 '26	Sale	108.81	50,000	5,440,500	12,480,400	Mar 13 05:02 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Mar 12 '26	Sale	108.68	50,000	5,433,806	12,430,400	Mar 13 05:02 PM
SCHWARTZ MARK S	V.P., C.A.O. and Treasurer	Feb 17 '26	Sale	110.00	3,150	346,500	12,080	Feb 18 04:17 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Feb 12 '26	Sale	110.27	50,000	5,513,500	12,859,642	Feb 17 05:02 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Feb 13 '26	Sale	108.87	50,000	5,443,500	12,809,642	Feb 17 05:02 PM
TISCH ANDREW H	Director Emeritus	Feb 13 '26	Proposed Sale	110.01	250,000	27,502,500		Feb 13 06:16 PM
BERMAN ANN E	Director	Feb 10 '26	Sale	110.16	1,922	211,728	4,998	Feb 11 04:21 PM
Alpert Marc A	Sr. VP, Gen. Coun. & Secy.	Feb 10 '26	Sale	109.87	3,495	383,983	16,325	Feb 11 04:15 PM
BERMAN ANN E	Director	Feb 10 '26	Proposed Sale	110.16	1,922	211,728		Feb 10 03:59 PM
Alpert Marc A	Officer	Feb 10 '26	Proposed Sale	109.59	3,495	383,017		Feb 10 09:39 AM
Wang Jane J.	Sr. Vice President & CFO	Feb 06 '26	Option Exercise	0.00	6,607	0	22,154	Feb 06 04:18 PM
Wang Jane J.	Sr. Vice President & CFO	Feb 05 '26	Option Exercise	0.00	5,475	0	17,787	Feb 06 04:18 PM
SIEGEL KENNETH I	Senior Vice President	Feb 06 '26	Option Exercise	0.00	6,607	0	17,433	Feb 06 04:17 PM
SIEGEL KENNETH I	Senior Vice President	Feb 05 '26	Option Exercise	0.00	5,475	0	13,065	Feb 06 04:17 PM
SCHWARTZ MARK S	V.P., C.A.O. and Treasurer	Feb 06 '26	Option Exercise	0.00	4,129	0	17,209	Feb 06 04:16 PM
SCHWARTZ MARK S	V.P., C.A.O. and Treasurer	Feb 05 '26	Option Exercise	0.00	3,422	0	14,314	Feb 06 04:16 PM
Alpert Marc A	Sr. VP, Gen. Coun. & Secy.	Feb 06 '26	Option Exercise	0.00	6,607	0	22,932	Feb 06 04:15 PM
Alpert Marc A	Sr. VP, Gen. Coun. & Secy.	Feb 05 '26	Option Exercise	0.00	5,475	0	18,564	Feb 06 04:15 PM
Locker Jonathan C	Director	Jan 01 '26	Option Exercise	0.00	1,288	0	24,990	Jan 05 04:25 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 15 '25	Sale	105.07	50,000	5,253,500	12,909,642	Dec 17 05:02 PM
SCOTT RICHARD WALDO	SVP & Chief Investment Officer	Dec 11 '25	Sale	104.74	1,000	104,740	32,901	Dec 12 04:15 PM
RICHARD W SCOTT	Officer	Dec 11 '25	Proposed Sale	104.74	1,000	104,740		Dec 11 04:11 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 04 '25	Sale	104.81	30,000	3,144,203	12,959,642	Dec 08 05:00 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 01 '25	Sale	107.05	40,000	4,281,990	13,019,642	Dec 03 05:59 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 03 '25	Sale	105.57	30,000	3,167,100	12,989,642	Dec 03 05:59 PM
HARRIS WALTER L	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	26,844	Dec 02 04:33 PM
HARRIS WALTER L	Director	Dec 01 '25	Sale	107.88	1,442	155,563	24,594	Dec 02 04:33 PM
FRIBOURG PAUL J	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	2,650	Dec 02 04:32 PM
FRIBOURG PAUL J	Director	Dec 01 '25	Sale	108.13	1,442	155,923	400	Dec 02 04:32 PM
DIKER CHARLES M	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	23,844	Dec 02 04:31 PM
DIKER CHARLES M	Director	Dec 01 '25	Sale	107.93	1,442	155,635	21,594	Dec 02 04:31 PM
BERMAN ANN E	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	8,936	Dec 02 04:30 PM
BERMAN ANN E	Director	Dec 01 '25	Sale	108.10	1,444	156,096	6,686	Dec 02 04:30 PM
TISCH ANDREW H	Director Emeritus	Dec 01 '25	Proposed Sale	107.87	200,000	21,574,000		Dec 01 05:28 PM
DIKER CHARLES M	Director	Dec 01 '25	Proposed Sale	107.93	1,442	155,642		Dec 01 11:51 AM
FRIBOURG PAUL J	Director	Dec 01 '25	Proposed Sale	108.12	1,442	155,916		Dec 01 11:34 AM
HARRIS WALTER L	Director	Dec 01 '25	Proposed Sale	107.88	1,442	155,563		Dec 01 11:31 AM
BERMAN ANN E	Director	Dec 01 '25	Proposed Sale	108.10	1,444	156,094		Dec 01 10:32 AM
FRIBOURG PAUL J	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	2,399	Sep 03 04:20 PM
FRIBOURG PAUL J	Director	Sep 02 '25	Sale	96.69	1,422	137,493	149	Sep 03 04:20 PM
BERMAN ANN E	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	8,685	Sep 03 04:19 PM
BERMAN ANN E	Director	Sep 02 '25	Sale	96.67	1,422	137,465	6,435	Sep 03 04:19 PM
DIKER CHARLES M	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	23,593	Sep 03 04:18 PM
DIKER CHARLES M	Director	Sep 02 '25	Sale	96.76	1,422	137,593	21,343	Sep 03 04:18 PM
HARRIS WALTER L	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	26,593	Sep 03 04:17 PM
HARRIS WALTER L	Director	Sep 02 '25	Sale	96.69	1,421	137,396	24,343	Sep 03 04:17 PM
DIKER CHARLES M	Director	Sep 02 '25	Proposed Sale	96.76	1,422	137,588		Sep 02 11:46 AM
BERMAN ANN E	Director	Sep 02 '25	Proposed Sale	96.67	1,422	137,466		Sep 02 11:41 AM
FRIBOURG PAUL J	Director	Sep 02 '25	Proposed Sale	96.69	1,422	137,491		Sep 02 11:35 AM
WELTERS ANTHONY	Director	Sep 02 '25	Proposed Sale	96.70	1,422	137,500		Sep 02 11:35 AM
HARRIS WALTER L	Director	Sep 02 '25	Proposed Sale	96.69	1,421	137,389		Sep 02 11:28 AM

GILD

Gilead Sciences Inc

L

Loews Corp

Upgrade your Finviz experience